tiprankstipranks
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
UK Market
0HD2
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (0HD2) Share Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

0HD2 Analyst Ratings

Strong Buy
19Ratings
Strong Buy
16 Buy
3 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HD2 Stock 12 Month Forecast

Average Price Target

$372.67
▲(30.39% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $372.67 with a high forecast of $550.00 and a low forecast of $230.00. The average price target represents a 30.39% change from the last price of $285.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"201":"$201","376":"$376","551":"$551","288.5":"$288.5","463.5":"$463.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":550,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$550.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":372.6666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$372.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[201,288.5,376,463.5,551],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.64,229.35999999999999,256.08,282.8,309.52,336.24,362.96000000000004,389.68,416.4,443.12,469.84000000000003,496.56,523.28,{"y":550,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.64,215.71897435897435,228.7979487179487,241.87692307692308,254.95589743589744,268.0348717948718,281.11384615384617,294.1928205128205,307.2717948717949,320.35076923076923,333.42974358974357,346.50871794871796,359.58769230769235,{"y":372.6666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,202.64,204.74461538461537,206.84923076923076,208.95384615384614,211.05846153846153,213.16307692307691,215.2676923076923,217.3723076923077,219.47692307692307,221.58153846153846,223.68615384615384,225.79076923076923,227.89538461538461,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":396.655,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":466.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.465,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.239,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.125,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.64,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$550.00Average Price Target$372.67Lowest Price Target$230.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on GB:0HD2
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$318
Buy
11.26%
Upside
Reiterated
08/13/26
Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus
Evercore ISI Analyst forecast on GB:0HD2
Cory Kasimov
Evercore ISI
Evercore ISI
$400→$325
Buy
13.71%
Upside
Reiterated
08/05/26
Alnylam price target lowered to $325 from $400 at Evercore ISIAlnylam price target lowered to $325 from $400 at Evercore ISI
H.C. Wainwright Analyst forecast on GB:0HD2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$485→$455
Buy
59.19%
Upside
Reiterated
08/04/26
H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on GB:0HD2
Danielle Brill
Truist Financial
Truist Financial
$410→$315
Buy
10.21%
Upside
Assigned
08/04/26
Truist Financial Releases a Buy Rating on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on GB:0HD2
Jessica Fye
J.P. Morgan
J.P. Morgan
$375
Buy
31.20%
Upside
Reiterated
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)
Canaccord Genuity Analyst forecast on GB:0HD2
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
50.09%
Upside
Reiterated
08/03/26
Canaccord Genuity Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Citi Analyst forecast on GB:0HD2
Eric Joseph
Citi
Citi
$380→$340
Buy
18.96%
Upside
Reiterated
08/03/26
Alnylam price target lowered to $340 from $380 at CitiAlnylam price target lowered to $340 from $380 at Citi
Barclays Analyst forecast on GB:0HD2
Eliana Merle
Barclays
Barclays
$527→$450
Buy
57.44%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)
Wells Fargo Analyst forecast on GB:0HD2
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$377→$316
Hold
10.56%
Upside
Reiterated
07/31/26
Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo
TD Cowen Analyst forecast on GB:0HD2
Ritu Baral
TD Cowen
TD Cowen
$482
Buy
68.64%
Upside
Assigned
07/31/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)
Jefferies Analyst forecast on GB:0HD2
Faisal Khurshid
Jefferies
Jefferies
$230
Hold
-19.53%
Downside
Reiterated
07/31/26
Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)
Raymond James Analyst forecast on GB:0HD2
Martin Auster
Raymond James
Raymond James
$468→$420
Buy
46.95%
Upside
Reiterated
07/31/26
Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James
Morgan Stanley Analyst forecast on GB:0HD2
Michael Ulz
Morgan Stanley
Morgan Stanley
$400→$300
Hold
4.96%
Upside
Reiterated
07/31/26
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
Oppenheimer Analyst forecast on GB:0HD2
Kostas Biliouris
Oppenheimer
Oppenheimer
$500→$350
Buy
22.45%
Upside
Reiterated
07/31/26
Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer
William Blair Analyst forecast on GB:0HD2
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on GB:0HD2
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$318
Buy
11.26%
Upside
Reiterated
08/13/26
Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus
Evercore ISI Analyst forecast on GB:0HD2
Cory Kasimov
Evercore ISI
Evercore ISI
$400→$325
Buy
13.71%
Upside
Reiterated
08/05/26
Alnylam price target lowered to $325 from $400 at Evercore ISIAlnylam price target lowered to $325 from $400 at Evercore ISI
H.C. Wainwright Analyst forecast on GB:0HD2
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$485→$455
Buy
59.19%
Upside
Reiterated
08/04/26
H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on GB:0HD2
Danielle Brill
Truist Financial
Truist Financial
$410→$315
Buy
10.21%
Upside
Assigned
08/04/26
Truist Financial Releases a Buy Rating on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on GB:0HD2
Jessica Fye
J.P. Morgan
J.P. Morgan
$375
Buy
31.20%
Upside
Reiterated
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)
Canaccord Genuity Analyst forecast on GB:0HD2
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$429
Buy
50.09%
Upside
Reiterated
08/03/26
Canaccord Genuity Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Citi Analyst forecast on GB:0HD2
Eric Joseph
Citi
Citi
$380→$340
Buy
18.96%
Upside
Reiterated
08/03/26
Alnylam price target lowered to $340 from $380 at CitiAlnylam price target lowered to $340 from $380 at Citi
Barclays Analyst forecast on GB:0HD2
Eliana Merle
Barclays
Barclays
$527→$450
Buy
57.44%
Upside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)
Wells Fargo Analyst forecast on GB:0HD2
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$377→$316
Hold
10.56%
Upside
Reiterated
07/31/26
Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo
TD Cowen Analyst forecast on GB:0HD2
Ritu Baral
TD Cowen
TD Cowen
$482
Buy
68.64%
Upside
Assigned
07/31/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)
Jefferies Analyst forecast on GB:0HD2
Faisal Khurshid
Jefferies
Jefferies
$230
Hold
-19.53%
Downside
Reiterated
07/31/26
Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)
Raymond James Analyst forecast on GB:0HD2
Martin Auster
Raymond James
Raymond James
$468→$420
Buy
46.95%
Upside
Reiterated
07/31/26
Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James
Morgan Stanley Analyst forecast on GB:0HD2
Michael Ulz
Morgan Stanley
Morgan Stanley
$400→$300
Hold
4.96%
Upside
Reiterated
07/31/26
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
Oppenheimer Analyst forecast on GB:0HD2
Kostas Biliouris
Oppenheimer
Oppenheimer
$500→$350
Buy
22.45%
Upside
Reiterated
07/31/26
Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer
William Blair Analyst forecast on GB:0HD2
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
25/40 ratings generated profit
63%
Average Return
+5.67%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +5.67% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
20/28 ratings generated profit
71%
Average Return
+23.94%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +23.94% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
28/40 ratings generated profit
70%
Average Return
+34.80%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +34.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HD2 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
19
24
34
32
Buy
19
17
14
19
16
Hold
6
7
6
10
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
43
44
63
55
In the current month, 0HD2 has received 48 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0HD2 average Analyst price target in the past 3 months is 372.67.
Each month's total comprises the sum of three months' worth of ratings.

0HD2 Financial Forecast

0HD2 Earnings Forecast

Next quarter’s earnings estimate for 0HD2 is $1.77 with a range of $1.04 to $2.97. The previous quarter’s EPS was $1.21. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HD2 is $1.77 with a range of $1.04 to $2.97. The previous quarter’s EPS was $1.21. 0HD2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Sales Forecast

Next quarter’s sales forecast for 0HD2 is $1.44B with a range of $1.37B to $1.49B. The previous quarter’s sales results were $1.29B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HD2 is $1.44B with a range of $1.37B to $1.49B. The previous quarter’s sales results were $1.29B. 0HD2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HD2 has Performed in-line its overall industry.

0HD2 Stock Forecast FAQ

What is GB:0HD2’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 372.67.
    What is GB:0HD2’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 30.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s share price target?
            The average share price target for Alnylam Pharmaceuticals is 372.67. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $550.00 ,and the lowest forecast is $230.00. The average share price target represents 30.39% Increase from the current price of $285.82.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Alnylam Pharmaceuticals?
                To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.